KRROFrequency Therapeutics
About Frequency Therapeutics
Frequency Therapeutics (NASDAQ:KRRO) is a biotechnology firm focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company's groundbreaking approach centers on activating progenitor cells to create functional tissue with the aim of developing therapies for conditions with significant unmet medical needs. At the forefront of its research and development efforts is a potential treatment for sensorineural hearing loss, reflecting the company's dedication to tackling complex health challenges through innovative regenerative medicine. Through its pioneering projects, Frequency Therapeutics seeks to transform the therapeutic landscape and improve the quality of life for patients worldwide.
What is KRRO known for?
Snapshot
Public US
Ownership
2014
Year founded
104
Employees
Massachusetts, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of Frequency Therapeutics
- FX-322, a drug designed to treat sensorineural hearing loss through the regeneration of inner ear sensory hair cells.
- Multiple sclerosis therapies focusing on remyelination of neurons to restore function and halt disease progression.
- Muscle regeneration product candidates targeting improvement in muscular diseases and injuries by enhancing regeneration and repair.
- FX-345, a newer development targeting specific types of inner ear damage for more precise hearing restoration.
- Skin regeneration projects aiming at wound healing and reduction of scarring through activation of skin progenitor cells.
- Neurodegenerative disease treatments, exploring ways to halt or reverse conditions such as Alzheimer's through cellular regeneration.
Frequency Therapeutics executive team
- Dr. Ram Aiyar MBA, Ph.D.CEO, President, Interim CFO, Principal Financial Officer & Director
- Mr. Jeffrey M. Cerio J.D., Pharm.D.Senior VP, General Counsel & Corporate Secretary
- Dr. Olukemi A. Olugemo M.D.Advisor
- Dr. Andrew Fraley Ph.D.Co-Founder & Advisor
- Dr. Joshua Rosenthal Ph.D.Co-Founder & Advisor
- Mr. Todd Chappell M.B.A.Chief Operating Officer
- Mr. Oliver DolanSenior VP of Finance & Principal Accounting Officer
- Dr. Loic Vincent Ph.D.Chief Scientific Officer
- Ms. Stephanie EngelsChief People Officer
- Dr. Gaozhong Zhu Ph.D.SVP of Chemistry, Manufacturing and Controls & Technical Operations